Methylenetetrahydrofolate reductase and psychiatric diseases. Issue 1 (December 2018)

• Record Type: Journal Article
• Authors: Wan, Lin; Li, Yuhong; Zhang, Zhengrong; Sun, Zuoli; He, Yi; Li, Rena
• Is Part Of: Translational psychiatry. Volume 8:Issue 1(2018)
• Page Start: 1
• Page End: 12
• Publication Date: 2018-12
• Subjects: Psychiatry -- Research -- Periodicals; Neurosciences -- Research -- Periodicals; Psychiatry -- Periodicals; Neurosciences -- Periodicals; Translational Research -- Periodicals; Health Policy -- Periodicals; Public Health -- Periodicals; 616.89
• DOI: 10.1038/s41398-018-0276-6
• Languages: English
• ISSNs: 2158-3188

Abstract

Abstract Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme for the critical process of one-carbon metabolism involving folate and homocysteine metabolisms. It is known that some polymorphism ofMTHFR would result in reduction of MTHFR enzyme activity as well as DNA methylation process, later shown to have significant impacts in various psychiatric diseases. However, it is unclear whether the polymorphism ofMTHFR could be an independent or an add-on risk factor for specific psychiatric symptoms, such as anxiety, depression, positive, or negative symptoms of schizophrenia, or acts as risk factor for specific psychiatric disorders, such as schizophrenia, major depression, autisms, and bipolar disorders. It is also understudied on whether folate supplements could be an effective treatment for psychiatric patients with defect MTHFR activity. In this review, we not only gathered the most recent discoveries onMTHFR polymorphism and related DNA methylation in various psychiatric disorders, but also highlighted the potential relationships between MTHFR activity and implication of folate-related function in specific mental diseases.